Bookimed does not add extra charges for Immunotherapy prices. The rates come from the clinics' official price lists. You pay directly at the clinic for your Immunotherapy upon your arrival.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Immunotherapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Immunotherapy journey.
| The USA | Turkey | Mexico | |
| Sarcoma Immunotherapy | from $10800 | from $3600 | from $4140 |
| Immunotherapy for prostate cancer | from $30000 | from $10000 | from $11500 |
| Immunotherapy for lung cancer | from $30000 | from $10000 | from $11500 |
| Immunotherapy for kidney cancer | from $30000 | from $10000 | from $11500 |
| Immunotherapy for breast cancer | from $30000 | from $10000 | from $11500 |
Quiron Barcelona Hospital is a top clinic in Spain, known for its advanced oncology care through the Baselga Institute of Oncology, which collaborates with leading American centers. With 23 operating rooms and cutting-edge technology like PET-CT and MRI, it offers precise and effective treatments, including robotized surgeries and assisted reproduction.
The hospital provides personalized care for international patients, with 165 wards, suites, and royal apartments. Services include tailored treatment plans, WiFi, airport transfers, and nearby hotel accommodations, making it a preferred choice for high-quality medical care.
Dr. Jaume Mora Graupera is a pediatric oncologist specializing in the treatment of neuroblastomas, gliomas, Ewing's sarcomas, and Wilms' tumors. He is the Director of the Hematology Oncology Department and Developmental Tumors Laboratory at Sant Joan De Déu - Barcelona Children’s Hospital. He received his medical degree from the University of Barcelona, went on to complete specialty training in pediatrics and fellowships in pediatric hematology oncology and molecular pathology of pediatric cancer at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in the USA. He has won multiple awards and is a member of various medical organizations.
This doctor has experience in endocrine treatment, collaborating on studies aimed at overcoming resistance to hormone therapy. They have also been involved in numerous phase 1, 2 and 3 studies in breast and melanoma, which have led to the approval of new drugs in new indications. Their main area of interest lies in immunotherapy for melanoma treatment and patient care. They have participated in trials that have led to the approval of cdk4/6 palbociclib and ribociclib inhibitors in the first line of metastatic breast cancer, and Pembrolizumab in the first line of metastatic melanoma, as well as the combination of Nivolumab and Ipilimumab. They are a member of the Breast Cancer Unit and Melanoma Unit at the Vall d'Hebron University Hospital and the Vall d'Hebron Institute of Oncology. This doctor is an experienced oncologist with expertise in breast cancer and melanoma treatments, including endocrine therapy, immunotherapy, and patient care. They have been involved in numerous clinical trials leading to the approval of new drugs in new indications.
Professor Bosch is a highly reputed leader in Chronic Lymphocytic Leukemia (CLL) and conducts clinical and basic research on CLL and other lymphoproliferative disorders, focusing on the molecular pathogenesis of CLL and new therapeutic approaches. He has published over 100 articles in prestigious journals and is a professor of haematology at the Vall d'Hebron University Hospital of Barcelona.